Wilson H. Miller
Jewish General Hospital(CA)
Publications by Year
Research Areas
Retinoids in leukemia and cellular processes, Cancer Immunotherapy and Biomarkers, Acute Myeloid Leukemia Research, Melanoma and MAPK Pathways, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- → Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma(2011)4,451 cited
- → Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial(2012)2,954 cited
- → Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial(2015)2,648 cited
- → Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma(2015)2,541 cited
- → Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma(2019)2,502 cited
- → Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study(2020)2,424 cited